Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | NRAS Q61R |
Therapy | RAF265 + Trametinib |
Indication/Tumor Type | urinary bladder cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NRAS Q61R | urinary bladder cancer | sensitive | RAF265 + Trametinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, RAF265 and Mekinist (trametinib) combination treatment decreased Erk1/2 phosphorylation in cultured cells and decreased tumor volume and weight of a cell line xenograft model harboring NRAS Q61R (PMID: 34554931). | 34554931 |
PubMed Id | Reference Title | Details |
---|---|---|
(34554931) | RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeutics. | Full reference... |